Clinical course of acute coronary syndrome under different pharmacological treatment strategies

2025

Full text Open access: Hybrid Metadata (CSL-JSON)
DOI 10.51582/interconf.19-20.04.2025.031
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Acute coronary syndrome (ACS) remains one of the leading causes of morbidity and mortality worldwide. The clinical course of ACS can vary significantly depending on the applied pharmacological treatment strategy. This study aims to evaluate and compare the effectiveness of different medication-based approaches in the management of ACS and their influence on clinical outcomes. A cohort of patients diagnosed with ACS was monitored and stratified according to the therapeutic regimens received, including antiplatelet therapy, anticoagulants, beta-blockers, statins, and other cardioprotective agents. Key clinical parameters such as recurrence of ischemic events, incidence of complications, and in-hospital mortality were analyzed. The results indicate that personalized selection and timely initiation of optimal pharmacotherapy significantly improve prognosis and reduce adverse cardiovascular events. These findings emphasize the importance of individualized therapeutic strategies in the management of ACS to achieve better clinical outcomes.